Dysglycemia in Pregnancy and Maternal/Fetal Outcomes

Corinne M. Silva, PhD, Matthew E. Arnegard, PhD, and Christine Maric-Bilkan, PhD

Abstract
Maternal dysglycemia—including diabetes, impaired glucose tolerance, and impaired fasting glucose—affects one in six pregnancies worldwide and represents a significant health risk to the mother and the fetus. Maternal dysglycemia is an independent risk factor for perinatal mortality, major congenital anomalies, and miscarriages. Furthermore, it increases the longer-term risk of type 2 diabetes mellitus, metabolic syndrome, cardiovascular morbidity, malignancies, and ophthalmic, psychiatric, and renal diseases in the mother. The most commonly encountered form of maternal dysglycemia is gestational diabetes. Currently, international consensus does not exist for diagnostic criteria defining gestational diabetes at 24–28 weeks gestation, and potential diagnostic glucose thresholds earlier in gestation require further investigation. Likewise, recommendations regarding the timing and modality (e.g., lifestyle or pharmacological) of treatment vary greatly. Because a precise diagnosis determines the appropriate treatment and outcome of the pregnancy, it is imperative that a better definition of maternal dysglycemia and its treatment be achieved. This article will address some of the controversies related to diagnosing and managing maternal dysglycemia. In addition, the article will discuss the impact of maternal dysglycemia on complications experienced by the mother and infant, both at birth and in later life.

Keywords: maternal dysglycemia, gestational diabetes, diagnostic criteria, maternal morbidity, offspring outcomes

Introduction

Glucose homeostasis during pregnancy is essential to the health of the mother and fetus. Maternal dysglycemia—including diabetes, impaired glucose tolerance, and impaired fasting glucose—is one of the most common complications of pregnancy. Indeed, maternal hyperglycemia currently affects approximately one in six pregnancies worldwide. The Centers for Disease Control and Prevention recently estimated the national prevalence of diabetes first diagnosed during pregnancy, known as gestational diabetes mellitus (GDM), to be 6%. The incidence of GDM and maternal dysglycemia more broadly is on the rise in the United States and globally.

Along with the increasing prevalence of maternal dysglycemia, the maternal mortality rate rose dramatically in the United States from 1987 to 2014 and remains high. In contrast, the rates of pregnancy-related deaths in high-income, peer countries of the United States decreased over the same period, as did the global average rate of maternal mortality. Instances of severe maternal morbidity (i.e., near misses for maternal mortality) also have become more common in the United States, affecting more than 50,000 women annually. Dysglycemia is one risk factor for severe maternal morbidity. Furthermore, maternal dysglycemia and maternal morbidity share common risk factors, such as advanced maternal age and obesity, both of which are increasing in prevalence globally.

GDM is the most often encountered form of maternal dysglycemia and is more common than pregestational diabetes (type 1 diabetes mellitus [T1DM] or type 2 diabetes mellitus [T2DM]). Currently, international consensus on the
Impacts of Maternal Dysglycemia on Maternal Outcomes

Pregnant women with any form of dysglycemia experience higher morbidity and mortality rates compared with normal pregnancies. The mortality rate in pregnant women with T1DM is twofold to threefold higher than for nonpregnant women with T1DM, and 5 to 20 times higher than the general obstetric population.\(^2\) The precise causes of mortality may be difficult to determine because mortality may be due to pregnancy complications, the presence of T1DM, or causes unrelated to either pregnancy or T1DM.\(^2\)

It has been reported that HbA\(_1c\) levels, albuminuria around the time of conception, and the presence of underlying conditions—such as hypertension and preeclampsia—are important determinants of maternal morbidity and mortality.\(^2\) If the hypertensive pregnancy is associated with renal dysfunction (serum creatinine >176 \(\mu\)mol/L or proteinuria in the nephrotic range [\(>3\) g/24 hour]) and/or preexisting cardiovascular disease (CVD), the risk for poor maternal outcomes increases further.\(^2\) The prevalence rates of hypertensive disorders of pregnancy—including chronic or gestational hypertension, preeclampsia/eclampsia, and chronic hypertension with superimposed preeclampsia—are particularly high among women with diabetes.\(^2\) Moreover, gestational dysglycemia increases the risk of postpartum hypertension.\(^2\)

The rate of C-sections has been reported to be higher among pregnant women with diabetes, mostly due to macrosomia.\(^2\) This observation is not universal, however, because some studies have reported no difference in C-section rates, at least between women with GDM and glucose-tolerant women.\(^2\) Women with T1DM exhibit severe rates, at least between women with GDM and glucose-tolerant women.\(^2\)

In many cases, metabolic abnormalities (e.g., obesity, hypertension) precede the diagnosis of GDM, and these women are at increased risk for developing T2DM and metabolic syndrome later in life.\(^3\) The reported incidence of the development of T2DM of women with GDM varies depending on the length of follow-up after pregnancy, diagnostic criteria, and the racial and ethnic makeup of the population studied. Retrospective studies find that women with GDM have a 20% to 60% risk of developing T2DM in the 5 to 10 years after pregnancy.\(^2\) One study showed that women with GDM have an almost eightfold higher risk of developing T2DM within 10 years, even after adjusting for socioeconomic status and body mass index (BMI).\(^3\) A more recent analysis from the U.S. National Health and Nutrition Examination Survey database showed that 19.7% of women who had GDM eventually developed T2DM.\(^3\)

Although T2DM is a known risk factor for CVD, some studies have addressed whether GDM is an independent risk factor for CVD. In a longitudinal analysis of the Coronary Artery Risk Development in Young Adults study, Gunderson et al.\(^5\) concluded that GDM was an independent risk factor for early atherosclerosis, even beyond that related to prepregnancy obesity. Accordingly, the American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) stress the importance of screening women with a prior diagnosis of GDM for disorders of glucose metabolism at least once every 3 years after their pregnancies.\(^3\) Not only does this screening have health implications for the mother, it also has important implications for subsequent pregnancy outcomes, including the health of her offspring.

Impacts of Maternal Dysglycemia on Offspring Outcomes

The most serious outcomes of diabetic pregnancies are neonatal mortality, stillbirth, preterm delivery (before 37 weeks of gestation), excessive fetal growth, and congenital abnormalities.\(^2\) Despite improvements in maternal glycemic monitoring and control, perinatal mortality rates and short-term complications continue to rise.\(^3\) The rates of perinatal mortality among women with either T1DM or T2DM are threefold to fourfold higher than among the general obstetric population.\(^3\) Although stillbirths remain a common outcome of diabetic pregnancies, lower rates of stillbirth have been reported recently, at least in some countries.\(^3\) which may be a result of improved preconception care and better glyemic control during pregnancy.

The mechanisms by which intrauterine exposure to maternal hyperglycemia translates to increased rates of fetal death, stillbirth, and preterm birth remain incompletely understood. It is thought that, because of the acquired dependence on maternal hyperglycemia in utero, babies born to mothers with GDM are at an increased risk for hypoglycemia at birth, which may lead to brain injury if left untreated.\(^3\)

Maternal hyperglycemia leads to fetal \(\beta\) cell hyperplasia and increased endogenous production of insulin and insulin-like growth factor 1.\(^3\) The resultant fetal hyperinsulinemia lowers fetal glucose levels, thus increasing the glucose concentration gradient across the placenta, driving glucose flux to the fetus.\(^3\) This persistent fetal hyperinsulinemia has adverse effects on offspring health, both short- and long-term. Fetal hyperinsulinemia, in turn, contributes to pancreatic \(\beta\) cell dysfunction and insulin resistance, even prenatally.\(^3\) Another neonatal complication of hyperglycemic pregnancy is respiratory distress syndrome. In particular, GDM is an independent risk factor for neonatal respiratory distress syndrome after 34 weeks of gestation.\(^5\) Although preterm delivery and asphyxia may be the cause of the increased incidence of respiratory distress syndrome in the infants of diabetic mothers, it also is thought that metabolic derangement, per se, may contribute to the inadequate production of pulmonary surfactant.\(^3\)

Uncontrolled maternal hyperglycemia leading to fetal hyperinsulinemia is associated with fetal growth acceleration and macrosomia (defined as a birth weight of \(>4.5\) kg and/or >90th percentile weight for gestational age).\(^2\) Macrosomia in offspring exposed to maternal hyperglycemia is associated with defects in many organs—including heart, kidney, liver, and pancreas.\(^3\) For example, hyperglycemia has been shown to alter the development and maturation of
fetal cardiomyocytes at genetic, structural, and functional levels, leading to fetal cardiomyopathy. Maternal hyperglycemia results in reduced nephron endowment in the fetal kidney, thus increasing the risk for hypertension and chronic kidney disease later in life.

Although birth defects resulting from diabetic pregnancy have been significantly reduced over the past two decades—in part because of improved glycemic control—the risk of congenital malformations in the offspring of mothers with diabetes remains twofold to fivefold higher than in normal pregnancies. Maternal hyperglycemia is associated with congenital heart, kidney and urinary tract, neural tube, and gut defects. The Type 2 Diabetes in Adolescents and Youth (TODAY) study, a recent randomized controlled trial designed to compare three treatment options for youth with T2DM, highlighted the severe effects of uncontrolled T2DM during pregnancy. Despite consent and extensive counseling to use contraception during the study to avoid pregnancy, 10% of the 452 girls enrolled became pregnant. Of these pregnancies, 26.4% resulted in miscarriage or stillbirth, and 20.5% of the live births had major congenital abnormalities.

Animal studies have shed some light on mechanisms of teratogenesis due to maternal diabetes. Reported mechanisms include “fuel-mediated teratogenesis” (i.e., increased delivery of glucose—including glucose and ketones—leading to biochemical disturbances in the fetus); insufficient apoptosis inhibition; and altered expression of developmental control genes (e.g., Pax3, Akt, JNK1/2, and Prk). Animal studies have shown that this transgenerational transmission of hyperglycemia is associated with epigenetic modifications in germ cells, such as a dysregulation of Igf2/H19 methylation in the pancreatic islet cells of offspring.

Studies in humans and experimental models have shown that an offspring exposed to maternal dysglycemia (due to GDM, T1DM, or T2DM) has a higher risk for CVD, obesity, GDM, T2DM, and associated metabolic diseases later in life, even after adjusting for confounders. Children of mothers with GDM, for example, are twice as likely to develop childhood obesity compared with offspring from normal pregnancies, even after adjusting for such confounders as maternal BMI. The fact that children of mothers with dysglycemia due to either T1DM or T2DM are at increased risk of developing this condition in their own pregnancies highlights the vicious intergenerational cycle of maternal dysglycemia.

Insufficient insulin production is one proposed mechanism behind the long-term metabolic consequences of intrauterine hyperglycemia for offspring. A study of 104 adult children of Pima Indians found decreased insulin response to glucose infusion (even in the absence of impaired glucose tolerance) only in offspring exposed to a diabetic environment in utero. This finding might explain the effect of maternal hyperglycemia on β cell programming in the fetus and its long-term consequences. Epigenetic alterations also have been suggested as a vehicle for transmitting maternal hyperglycemia to the offspring and affecting their long-term health.

Studies in animals show that adverse offspring outcomes of maternal hyperglycemia are largely preventable by normalized maternal blood glucose levels. The extents to which tighter control of maternal hyperglycemia in humans can prevent long-term consequences of maternal dysglycemia for offspring remain to be elucidated. Long-term follow-up studies have been lacking in this regard. Basic research aimed at better understanding the mechanisms underlying the long-term consequences of maternal hyperglycemia for offspring are also needed.

Diagnosis and Management of Maternal Dysglycemia

Because of the risks that maternal dysglycemia poses for both mother and offspring, it is important to know how to define GDM, as well as how and when blood glucose levels and glucose tolerance should be measured. Furthermore, if GDM is diagnosed, it is critical to know how it should be treated, while considering both the immediate effects during pregnancy and long-term outcomes for mothers and their offspring. Clarifying these issues is not straightforward, and current recommendations vary across countries and even among U.S. medical centers.

GDM, as defined by the Fifth International Workshop Conference on Gestational Diabetes Mellitus, is glucose intolerance with onset or first recognition during pregnancy. Current practice guidelines recommend testing for GDM at 24-28 weeks of pregnancy (just before or during the third trimester). The ACOG recommends a two-step process. The first step (screening) involves giving the pregnant woman a 50-g glucose load in a nonfasting state. If, after 1 hour, the plasma glucose level is above a threshold (ranging from 130 to 140 mg/dL, depending on guidelines where the screening is being performed), the second step is followed. The second step (oral glucose tolerance test) involves administering a 100-g glucose load after an overnight fast. Plasma glucose is measured before the glucose load and again after 1, 2, and 3 hours. If two of these four values exceed certain levels, GDM is diagnosed: fasting (>95 mg/dL), 1 hour (>180 mg/dL), 2 hours (>155 mg/dL), and 3 hours (>140 mg/dL). Most U.S. medical centers and hospitals adhere to this two-step process. In contrast, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and World Health Organization (WHO) recommend a one-step test. The plasma glucose level is measured after an overnight fast and then again at 1 and 2 hours after a 75-g glucose load. If only one of these plasma glucose measures is higher than the predefined levels (fasting, 92 mg/dL; 1 hour, 180 mg/dL; 2 hours, 153 mg/dL), then a diagnosis of GDM is made. According to these international criteria, 18% of pregnant women in the United States would be diagnosed with GDM.

The differences in screening procedures described above resulted from the international Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study, funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The HAPO study was designed to clarify the risks of adverse outcomes associated with degrees of maternal glucose intolerance less severe than those found with overt diabetes during pregnancy. An ethnically diverse group of 25,505 women was recruited from across 15 centers and 9 countries. Women were given a 75-g oral glucose tolerance test at 24-32 weeks of pregnancy (levels measured at fasting, 1 hour, and 2 hours) and another random glucose measurement at 34-37 weeks. The results from 2.9% of the women analyzed reached...
glucose levels either diagnostic of overt diabetes or above predetermined safety levels and thus were not included in further analysis. Primary outcomes for those remaining in the study were as follows: birth weight >90th percentile, primary cesarean section delivery, clinically defined neonatal hypoglycemia, and cord C-peptide >90th percentile. Secondary outcomes were preeclampsia, preterm delivery, shoulder dystocia or birth injury, hyperbilirubinemia, and intensive neonatal care.26

The results of the HAPO study showed that glucose levels below those that currently were used to diagnose GDM demonstrated a linear association with increased risks for both mother and baby, including the need for cesarean section, high birth weight, and low neonatal blood glucose level at birth. There also were significant associations with secondary outcomes, although they were somewhat weaker.26 Furthermore, at ~11 years after delivery, mothers (and children) from the HAPO study were followed up for metabolic analysis. Of the 4,697 mothers who took part in the HAPO follow-up study, 14% would have been diagnosed with GDM during their pregnancy under the stricter IADPSG criteria. In fact, more than half of these women had developed either T2DM or prediabetes.72 Along with the other factors that also were measured—including age, BMI, and family history—this HAPO follow-up study showed that increased glucose levels during pregnancy were an independent risk factor for the development of diabetes in the mother 11 years after pregnancy. Furthermore, the children of these mothers (average age, 11 years) had increased measures of adiposity compared with those whose mothers did not have GDM during their pregnancy.73,74

With the increasing incidence of obesity and maternal age, the prevalence of both GDM and overt diabetes first detected during pregnancy are increasing.75–79 Many of these high-risk women are being screened for overt diabetes or GDM early in pregnancy.77 However, no consensus yet exists regarding when to measure and how to treat GDM. A 2014 U.S. Preventive Services Task Force (USPSTF) review concluded that evidence was insufficient to recommend either for or against GDM screening before 24 weeks of pregnancy, given the lack of consistent evidence for a treatment effect on either maternal or infant outcomes.80

Insulin resistance and, therefore, plasma glucose levels are known to increase throughout pregnancy.81,82 The natural change in glucose metabolism during pregnancy complicates the diagnosis of GDM. In July 2018, the ADA published a Special Article Collection in Diabetes Care titled “Reconsidering Pregnancy with Diabetes,” highlighting the importance of addressing diagnostic criteria, outcomes for both mother and baby, and comparison of treatment paradigms, both lifestyle based and pharmacological (e.g., metformin, glyburide, insulin).83–88

In 2017, NIDDK sponsored a workshop to identify research gaps in GDM diagnosis and treatment. Like the USPSTF in 2014, the workshop proceedings’ concluded evidence was insufficient to either support or rule out screening for GDM before 24 weeks of gestation.89,90 The workshop highlighted the need for further studies, not only to define diagnostic criteria but to identify alternative markers (beyond glucose measurements) and, ultimately, to determine the effects of early GDM diagnosis and treatment on maternal and birth outcomes.89,90

Following the recommendations of this workshop, an NIDDK-funded study will investigate the use of continuous glucose-monitoring devices to better understand how glucose levels change during pregnancy and whether glucose levels early in pregnancy reflect those measured at 24–28 weeks. Results from this study should help define the parameters for future studies to assess the potential benefits of treatment strategies during pregnancy that may lead to better outcomes for mothers, for babies at birth, and for long-term maternal and offspring health.

Conclusion

Although tremendous progress has been made in understanding the adverse outcomes of maternal dysglycemia for mothers and their offspring, important knowledge gaps remain in terms of the mechanisms underlying these effects. It is also essential to achieve a better understanding of the course of maternal dysglycemia and its diagnosis. Only when there is a precise diagnosis of this condition will the most appropriate treatment be determined. This knowledge is critical to improving maternal glucose homeostasis and, in turn, the course and outcome of pregnancy.

ACOG and WHO recognize that improving the health of mothers and newborns depends on the continuity of pre-pregnancy, antenatal, and postpartum care.91,92 The effects of maternal dysglycemia on mothers later in life and the trans-generational cycle of metabolic disease risk rooted in maternal dysglycemia illustrate the added importance of broadening this continuum to the entire course of a woman’s life and even across generations. Research in the context of an integrative life-course framework will help advance the diagnosis, prevention, and treatment of maternal dysglycemia to the benefit of mothers, offspring, and future generations.

Author Disclosure Statement

No competing financial interests exist.

Funding Information

No funding was received for this article.

References

1. International Diabetes Federation. IDF Diabetes Atlas, 9th ed. Brussels: International Diabetes Federation, 2019.
2. Deputy NP, Kim SY, Conrey EJ, Bullard KM. Prevalence and changes in preexisting diabetes and gestational diabetes among women who had a live birth—United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2018;67:1201–1207.
3. Ferrara A. Increasing prevalence of gestational diabetes mellitus: A public health perspective. Diabetes Care 2007; 30:S141–S146.
4. Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007; 34:173–199.
5. Gray SG, Sweeting AN, McGuire TM, Cohen N, Ross GP, Little PJ. Changing environment of hyperglycemia in pregnancy: Gestational diabetes and diabetes mellitus in pregnancy. J Diabetes 2018;10:633–640.
6. Centers for Disease Control and Prevention. Pregnancy Mortality Surveillance System. 2020. Available at https://www.cdc.gov/reproductivehealth/maternalinfanthealth/
pregnancy-mortality-surveillance-system.htm Accessed March 22, 2020.
7. Petersen EE, Davis NL, Goodman D, et al. Vital signs: Pregnancy-related deaths, United States, 2011–2015, and strategies for prevention, 13 states, 2013–2017. MMWR Morbid Mortal Wkly Rep 2019;68:423–429.
8. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1775–1812.
9. Fingar K, Hambrick MM, Heslin KC, Moore JE. Trends and Disparities in Delivery Hospitalizations Involving Severe Maternal Morbidity, 2006–2015. Rockville, MD: Agency for Healthcare Research and Quality, 2018.
10. Centers for Disease Control and Prevention. Severe maternal morbidity and mortality in the United States. 2020. Available at: https://www.cdc.gov/reproductivehealth/maternalinfanthealth/severematernalmorbidity.html Accessed March 22, 2020.
11. Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012;120:1029–1036.
12. Grobman WA, Bailit JL, Rice MM, et al. Frequency of and factors associated with severe maternal morbidity. Obstet Gynecol 2014;123:804–810.
13. Negro CA, Montenegro RM Jr., Mattar R, et al. Dysglycemias in pregnancy: From diagnosis to treatment. Brazilian consensus statement. Diabet Metab Syndr 2010;2:27.
14. Lisonkova S, Muraca GM, Potts J, et al. Association between prepregnancy body mass index and severe maternal morbidity. JAMA 2017;318:1777–1786.
15. Domanski G, Lange AE, Ittermann T, et al. Evaluation of neonatal and maternal morbidity in mothers with gestational diabetes: A population-based study. BMC Pregnancy Childbirth 2018;18:367.
16. Aoyama K, Pinto R, Ray JG, et al. Association of maternal age with severe maternal morbidity and mortality in Canada. JAMA Netw Open 2019;2:e199975.
17. Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol 2018;131:e49–e64.
18. Stogianni A, Landin-Olsson M, Thunander M. Obstetric and perinatal outcomes in pregnancies complicated by diabetes, and control pregnancies, in Kronoberg, Sweden. BMC Pregnancy Childbirth 2019;19:159.
19. Ranj PR, Begum J. Screening and diagnosis of gestational diabetes mellitus: Where do we stand? J Clin Diagn Res 2016;10:QE01–QE04.
20. Behboudi-Gandevani S, Amir M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: A systematic review and meta-analysis. Diabetol Metab Syndr 2019;11:11.
21. Huhn EA, Rossi SW, Hoesli I, Gobl CS. Controversies in screening and diagnostic criteria for gestational diabetes in early and late pregnancy. Front Endocrinol (Lausanne) 2018;9:696.
22. Leinonen PJ, Hiilesmaa VK, Kaaja RJ, Teramo KA. Maternal mortality in type 1 diabetes. Diabetes Care 2001;24:1501–1502.
23. Knorr S, Juul S, Bytoft B, et al. Impact of type 1 diabetes on maternal long-term risk of hospitalisation and mortality: A nationwide combined clinical and register-based cohort study (The EPICOM study). Diabetologia 2018;61:1071–1080.
42. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. Int J Mol Sci 2018;19:3342.

43. Desoye G, Nolan CJ. The fetal glucose steal: An under-appreciated phenomenon in diabetic pregnancy. Diabetologia 2016;59:1089–1094.

44. Fetita LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab 2006;91:3718–3724.

45. Mortier I, Blanc J, Bosello B, Gire C, Bretelle F, Carcoppino X. Is gestational diabetes an independent risk factor of neonatal severe respiratory distress syndrome after 34 weeks of gestation? A prospective study. Arch Gynecol Obstet 2017;296:1071–1077.

46. Tydén O, Eriksson UJ, Armitage JA, et al. Maternal glucose intolerance reduces offspring nephron endowment and increases glomerular volume in adult offspring. Diabetes Metabol Res Rev 2016;32:816–826.

47. The Diabetes Control and Complications Trial Research Group. Pregnancy outcomes in the Diabetes Control and Complications Trial. Am J Obstet Gynecol 1996;174:1343–1353.

48. Eriksson NB, Damm P, Mathiesen ER, Ringholm L. The prevalence of congenital malformations is still higher in pregnant women with pregestational diabetes despite near-normal HbA1c: A literature review. J Matern Fetal Neonatal Med 2019;32:1225–1229.

49. Zabihi S, Loeken MR. Understanding diabetic teratogenesis: Where are we now and where are we going? Birth Defects Res A Clin Mol Teratol 2010;88:779–790.

50. Petitti LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab 2006;91:3718–3724.

51. Ding G-L, Wang F-F, Shu J, et al. Transgenerational glucose intolerance with Igf2/H19 epigenetic alterations in mouse islet induced by intrauterine hyperglycemia. Diabetes 2012;61:1133–1142.

52. Clausen TD, Mathiesen ER, Hansen T, et al. High prevalence of type 2 diabetes and pre-diabetes in adult offspring of women with gestational diabetes mellitus or type 1 diabetes: The role of intrauterine hyperglycemia. Diabetes Care 2008;31:340–346.

53. Hummel S, Much D, Rossbauer M, Ziegler AG, Beyerlein A. Postpartum outcomes in women with gestational diabetes and their offspring: POGO study design and first-year results. Rev Diabet Stud 2013;10:49–57.

54. Tam WH, Ma RCW, Ozaki R, et al. In utero exposure to maternal hyperglycemia increases childhood cardiometabolic risk in offspring. Diabetes Care 2017;40:679–686.

55. Lee SC, Pui YB, Chow CC, et al. Diabetes in Hong Kong Chinese: Evidence for familial clustering and parental effects. Diabetes Care 2000;23:1365–1368.

56. Yang P, Reece EA, Wang F, Gabbay-Benziv R. Decoding the oxidative stress hypothesis in diabetic embryopathy through proapoptotic kinase signaling. Am J Obstet Gynecol 2015;213:526–528.

57. Lowe WL Jr., Scholtens DM, Lowe LP, et al. Maternal glucose intolerance reduces offspring nephron endowment and increases glomerular volume in adult offspring. Diabetes Metabol Res Rev 2016;32:816–826.

58. Lapolla A, Metzger BE. The post-hAPO situation with gestational diabetes: The bright and dark sides. Acta Diabetol 2018;55:885–892.

59. Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007;30:S251–S260.

60. International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010;33:676–682.

61. World Health Organization (WHO). Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva, Switzerland: WHO, 2013.

62. Sacks DA, Hadden DR, Marashi M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Diabetes Care 2012;35:526–528.

63. Lowe WL Jr., Scholtens DM, Lowe LP, et al. Association of gestational diabetes with maternal disorders of glucose metabolism and childhood adiposity. JAMA 2018;320:1005–1016.

64. Lowe WL Jr., Lowe LP, Kuan A, et al. Maternal glucose levels during pregnancy and childhood adiposity in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Diabetologia 2019;62:598–610.

65. Lowe WL Jr., Scholtens DM, Kuan A, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal gestational diabetes mellitus and childhood glucose metabolism. Diabetes Care 2019;42:372–380.

66. Kim SY, England L, Wilson HG, Bish C, Satten GA, Dietz P. Percentage of gestational diabetes mellitus attributable to overweight and obesity. Am J Public Health 2010;100:1047–1052.
76. Makgoba M, Savvidou M, Steer P. An analysis of the interrelationship between maternal age, body mass index and racial origin in the development of gestational diabetes mellitus. BJOG 2012;119:276–282.
77. Chen C, Xu X, Yan Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. PLoS One 2018;13:e0202183.
78. Shan D, Qiu P-Y, Wu Y-X, et al. Pregnancy outcomes in women of advanced maternal age: A retrospective cohort study from China. Sci Rep 2018;8:12239.
79. Londero AP, Rossetti E, Pittini C, Cagnacci A, Driul L. Maternal age and the risk of adverse pregnancy outcomes: A retrospective cohort study. BMC Pregnancy Childbirth 2019;19:261.
80. Moyer VA, U.S. Preventive Services Task Force. Screening for gestational diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2014;160:414–420.
81. Sonagra AD, Biradar SM, Dattatreya K, Murthy DSJ. Normal pregnancy—A state of insulin resistance. J Clin Diagn Res 2014;8:CC01–CC03.
82. Kampmann U, Knorr S, Fuglsang J, Ovesen P. Determinants of maternal insulin resistance during pregnancy: An updated overview. J Diabetes Res 2019;2019:5320156.
83. Cheung NW, Moses RG. Gestational diabetes mellitus: Is it time to reconsider the diagnostic criteria? Diabetes Care 2018;41:1337–1338.
84. McIntyre HD, Jensen DM, Jensen RC, et al. Gestational diabetes mellitus: Does one size fit all? A challenge to uniform worldwide diagnostic thresholds. Diabetes Care 2018;41:1339–1342.
85. Hernandez TL, Brand-Miller JC. Nutrition therapy in gestational diabetes mellitus: Time to move forward. Diabetes Care 2018;41:1343–1345.
86. Yamamoto JM, Kellett JE, Balsells M, et al. Gestational diabetes mellitus and diet: A systematic review and meta-analysis of randomized controlled trials examining the impact of modified dietary interventions on maternal glucose control and neonatal birth weight. Diabetes Care 2018;41:1346–1361.
87. Stewart ZA, Wilinska ME, Hartnell S, et al. Day-and-night closed-loop insulin delivery in a broad population of pregnant women with type 1 diabetes: A randomized controlled crossover trial. Diabetes Care 2018;41:1391–1399.
88. Benhalima K, Van Crombrugge P, Moyson C, et al. The sensitivity and specificity of the glucose challenge test in a universal two-step screening strategy for gestational diabetes mellitus using the 2013 World Health Organization criteria. Diabetes Care 2018;41:e111–e112.
89. Bremer AA. Commentary: Research gaps in gestational diabetes mellitus: Executive summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop. Front Endocrinol (Lausanne) 2018;9:627.
90. Wexler DJ, Powe CE, Barbour LA, et al. Research gaps in gestational diabetes mellitus: Executive summary of a National Institute of Diabetes and Digestive and Kidney Diseases workshop. Obstet Gynecol 2018;132:496–505.
91. Firoz T, McCaw-Binns A, Filippi V, et al. A framework for health care interventions to address maternal morbidity. Int J Gynaecol Obstet 2018(Suppl 1):141:61–68.
92. Presidential Task Force on Redefining the Postpartum Visit Committee on Obstetric Practice. ACOG Committee Opinion No. 736: Optimizing postpartum care. Obstet Gynecol 2018;131:e140–e150.

Address correspondence to:
Christine Maric-Bilkan, PhD
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
6707 Democracy Boulevard
Bethesda, MD 20892
USA

E-mail: christine.maric-bilkan@nih.gov